Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang,

Slides:

Advertisements

Similar presentations

Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic.

Advertisements

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma Yirui Zhai, MD, Zhouguang Hui, MD, Wei Ji, MD, Xiaozhen Wang,

Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients Ze Fen Xiao, MD, Zong Yi Yang, MD, Jun Liang, MD, Yan.

Association of Perioperative Fluid Balance and Adverse Surgical Outcomes in Esophageal Cancer and Esophagogastric Junction Cancer Shenhai Wei, MD, PhD,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Collision Tumor of Esophagus: Report of Three Cases

Joshua E. Rosen, BASc, Hari B

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma Jeeyun Lee, MD, Kyoung-Eun.

Extraesophageal Saline During Endoscopic Submucosal Dissection in a Patient With Early Esophageal Squamous Cell Carcinoma Jian-jun Li, MD, PhD, Hong-bo.

Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.

Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma Giulio Melloni, MD, Claudio.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Prognostic Value of Different Lymph Node Staging Methods in Esophageal Squamous Cell Carcinoma After Esophagectomy San-Gang Wu, MD, Feng-Yan Li, MD,

The Impact of Peripheral Vascular Disease on Long-Term Survival After Coronary Artery Bypass Graft Surgery Danny Chu, MD, Faisal G. Bakaeen, MD, Xing.

High Expression of Zinc-Binding Protein-89 Predicts Decreased Survival in Esophageal Squamous Cell Cancer Shu-Mei Yan, MD, Hui-Ni Wu, MB, Fan He, MD,

Castigliano M. Bhamidipati, DO, MS, George J

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer Servet Bölükbas,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Anthony Lemaire, MD, William R

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Pulmonary Resection in the Treatment of Multidrug-Resistant Tuberculosis: A Retrospective Study of 56 Cases Haifeng Wang, MM, Hongsheng Lin, MM, Gening.

Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma:

Established Preoperative Risk Factors Do Not Predict Long-Term Survival in Isolated Coronary Artery Bypass Grafting Patients Giovanni Filardo, PhD, MPH,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Sam Chitsaz, MD, Nicolas Jaussaud, MD, Edward Chau, MD, Kimberly S

Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma Chen-Sung Lin, MD, PhD, Chih-Tao Cheng, MD, DrPH, Chao-Yu.

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence Balu Bhaskar, MD, FCICM, Joel Dulhunty, PhD,

Comparison of the 6th and 7th Editions of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System in Patients With Resected Esophageal.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J

Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.

Primary Cardiac Sarcoma

Kathryn E. Engelhardt, MD, Malcolm M. DeCamp, MD, Anthony D

Surgical Repair for Acute Type A Aortic Dissection in Octogenarians

Radiofrequency Ablation for the Treatment of Pulmonary Metastases

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Postoperative Extracorporeal Membrane Oxygenation Support for Acute Type A Aortic Dissection Ting-Wei Lin, MD, MS, Meng-Ta Tsai, MD, Yu-Ning Hu, MD,

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide.

Primary Small Cell Carcinoma of the Esophagus

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Prognostic Analysis for Survival After Resections of Localized Primary Cardiac Sarcomas: A Single-Institution Experience Hua Li, MD, PhD, Deming Xu,

Complete Intramural Esophageal Dissection Caused by Violent Vomiting

Daniel A. Anaya, MD, Mujun Yu, MD, Riyad Karmy-Jones, MD

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

Modern Outcome and Risk Analysis of Surgically Resected Occult N2 Non-Small Cell Lung Cancer Hyun Jin Cho, MD, Sung Ryong Kim, MD, Hyeong Ryul Kim, MD,

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Kim I. de la Cruz, MD, Faisal G

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Presentation transcript:

Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang, MD, Chao Ren, MD, Hui-Yan Luo, MD, Feng-hua Wang, MD, PhD, Yu-Hong Li, MD, PhD, Dong-Sheng Zhang, MD, PhD, Rui-Hua Xu, MD, PhD The Annals of Thoracic Surgery Volume 97, Issue 6, Pages 1975-1981 (June 2014) DOI: 10.1016/j.athoracsur.2014.02.037 Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Kaplan-Meier survival curves. (A) Patients with diagnoses of small cell carcinoma of the esophagus. (B) Patients without lymph node involvement had better survival than those with lymph node metastases (28.0 vs 9.5, p < 0.001). (C) Patients with distant metastases had inferior MST compared with patients with localized lesions (8.8 vs 16.8 months, p < 0.001). The Annals of Thoracic Surgery 2014 97, 1975-1981DOI: (10.1016/j.athoracsur.2014.02.037) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Kaplan-Meier survival curves. (A) Survival of patients who received surgical treatment versus that of patients who did not in subset I/IIA. (B) Survival of patients who received surgical treatment and chemotherapy (1 induction chemotherapy and 23 adjuvant chemotherapy) versus that of patients who received surgical treatment alone in subset I/IIA. (C) Survival of patients who received chemotherapy versus that of patients who did not in subset IIB/III. (D) Survival of patients who received radiotherapy in addition to chemotherapy (7 induction chemotherapy, 2 chemoradiotherapy, and 2 adjuvant chemotherapy) versus that of patients who received surgical treatment in combination with chemotherapy (3 induction chemotherapy and 28 adjuvant chemotherapy). (E) Survival of patients who received surgical treatment versus that of patients who did not in subset IIB/III. (F) Survival of patients who received radiotherapy versus that of patients who did not in subset IIB/III. The number of patients at risk in each group is given below the graph. (C = chemotherapy; S = surgical treatment; MST = median survival time; R = radiotherapy.) The Annals of Thoracic Surgery 2014 97, 1975-1981DOI: (10.1016/j.athoracsur.2014.02.037) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Kaplan-Meier survival curves. (A) Survival of patients who received chemotherapy versus that of patients who did not in subset IV. (B) Survival of patients who received chemotherapy and radiotherapy versus that of patients with chemotherapy alone in subset IV. (C) Survival of patients who received surgery versus that of patients without surgery in subset IV. (D) Survival of patients who received radiotherapy versus that of patients without radiotherapy in subset IV. (MST = median survival time.) The Annals of Thoracic Surgery 2014 97, 1975-1981DOI: (10.1016/j.athoracsur.2014.02.037) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions